Authors


Skye C. Mayo, MD, MPH

Latest:

Surgical Management of Neuroendocrine Tumors: Treatment of Localized and Metastatic Disease

Tumors of neuroendocrine origin arising from the pancreas, luminal gastrointestinal tract, and other tissues differ greatly in their malignant potential.


Snehal G. Patel, MD

Latest:

The Role of Neck Dissection Following Definitive Chemoradiation

The presence of regional nodal metastases represents a significantadverse prognostic factor for patients with squamous cell carcinoma ofthe head and neck. Early-stage head and neck cancers, localized to theprimary site without regional lymph node metastases have excellentcure rates with either surgery or radiation therapy. The presence ofregional metastases results in cure rates that are approximately half ofthose obtainable in early-stage disease. Therefore, due to the significantadverse impact of neck metastases on prognosis, the treatment ofthe neck remains a vital part of the decision-making process in determiningtherapy for head and neck cancer.


Sofia Cañete, MD

Latest:

The Variegated Morphology of HPV-Related Neoplasms of the Penis

Our commentary aims to expand on the evolution and present state of the art in the pathology of HPV in penile cancer and precancerous lesions.


Sofia D. Merajver, MD, PhD

Latest:

Molecular Determinants of the Inflammatory Breast Cancer Phenotype

Since its early descriptions by Lee and Tannenbaum in 1924, inflammatory breast cancer (IBC) has been recognized as the most aggressive and lethal form of primary breast cancer. With distinct clinical, pathologic, biologic, and molecular features, IBC presents unique challenges and opportunities to breast oncologists and breast cancer researchers.


Soham Puvvada, MD

Latest:

Radiotherapy Is NOT Essential to Cure Diffuse Large B-Cell Non-Hodgkin Lymphoma

DLBCL of any stage remains a systemic disease with early hematogenous spread. Thus, arguments advocating the role of IFRT do not truly address disease biology, and all future efforts to cure patients will require improved systemic therapy.


Solange Pendas, MD

Latest:

Lymphatic Mapping in the Treatment of Breast Cancer

Developed initially for the treatment of malignant melanoma, lymphatic mapping and sentinel lymph node biopsy have recently been introduced into the treatment of early breast cancer. In breast cancer patients, harvested


Soledad Retamozo, MD

Latest:

Cryoglobulinemic Disease

In spite of the complicated etiologic, clinical, and pathologic scenario of cryoglobulinemia, physicians can play a key role in its successful management by early recognition of the most common clinical presentations.


Sonali Jindal, MD

Latest:

Diagnosis of Invasive Lobular Carcinoma in a Young Woman Presenting With Pleomorphic Lobular Carcinoma in Situ on Core Biopsy

A 40-year-old premenopausal woman with a new diagnosis of invasive lobular carcinoma occurring in a background of lobular carcinoma in situ presents to a multidisciplinary second opinion clinic.


Sonali M. Smith, MD

Latest:

Follicular Lymphoma: a Focus on Current and Emerging Therapies

This review article written by Kirk E. Cahill, MD, and Sonali M. Smith, MD, discusses standard and emerging therapies for the treatment of follicular lymphoma.


Sonam Sharma, MD

Latest:

Prophylactic Cranial Irradiation Improved Survival in Metastatic SCLC

This video examines the results of a retrospective study that compared chemotherapy alone or with prophylactic cranial irradiation in extensive-stage SCLC patients with no brain metastases.


Sonia Castillo, PhD

Latest:

Deferasirox for the Treatment of Chronic Iron Overload in Transfusional Hemosiderosis

This report describes the Food and Drug Administration's review of data and analyses leading to the approval of the oral iron chelator, deferasirox for the treatment of chronic iron overload due to transfusional hemosiderosis.


Sonia Partap, MD, MS

Latest:

Highlighting Childhood Brain Cancers

In this interview we discuss updates, challenges, and contributing factors associated with pediatric brain cancers.


Sonja Chandler, PharmD

Latest:

An Alternative Algorithm for Dosing Transdermal Fentanyl for Cancer-Related Pain

Many cancer patients are undermedicated and inappropriately managed for pain, leading to a diminished quality of life. Patients with moderate to severe pain often require opioid analgesics. Recently published guidelines


Sophia Abraham, PhD

Latest:

Topotecan in Combination With Cisplatin for the Treatment of Stage IVB, Recurrent, or Persistent Cervical Cancer

Topotecan, a camptothecin analog previously approved for the treatment of ovarian cancer and small-cell lung cancer, was granted regular approval by the US Food and Drug Administration (FDA) on June 14, 2006, for use in combination with cisplatin to treat women with stage IVB, recurrent, or persistent carcinoma of the cervix not amenable to curative treatment with surgery and/or radiation therapy. The purpose of this summary is to review the database supporting this approval.


Sotaro Sadahiro, MD

Latest:

A Novel Weekday - on/Weekend - off UFT Schedule

In a step toward a clinical trial, the tumor response and survival of a weekday-on/weekend-off schedule of UFT was compared with its conventional daily schedule in a cancer-bearing rat model. The dose-intensive schedule-600 mg of UFT for 5 days followed by 2 drug-free days-amounts to a weekly dose similar to the conventional schedule of 400 mg/day. The weekday-on/weekend-off schedule provided increased survival and significantly greater antitumor activity than the conventional daily schedule, with no difference in adverse reactions.


Srdan Verstovsek, MD, PhD

Latest:

Momelotinib May Become ‘No. 1 Choice’ for Second-Line Therapy in Myelofibrosis, Expert Says

Momelotinib continues to show benefit in reducing splenic symptoms and anemia in myelofibrosis in the second-line setting, making it a likely first treatment choice, according to an expert from the University of Texas MD Anderson Cancer Center.


Sreekanth Reddy, MD

Latest:

Race and Cancer Genetics: Lessons From BRCA1

The study of cancer in specific populations can offer clues useful in determining the extrinsic and intrinsic factors influencing cancer in all populations. Extrinsic factors are sometimes called "environmental" in the broadest sense of the word. They are modifiable or mutable. Intrinsic factors are more inherent to the individual. They are almost always genetic and are immutable or unchangeable. Targeting research on specific populations is and should be a significant ethical issue.


Sreenivasa Nattam, MD

Latest:

Gemcitabine, Paclitaxel, and Trastuzumab in Metastatic Breast Cancer

A phase II trial evaluated the effectiveness and toxicity of combination paclitaxel (Taxol), gemcitabine (Gemzar), and trastuzumab (Herceptin) as first-line therapy for patients with newly diagnosed HER2-overexpressing


Sri Gururangan, MRCP

Latest:

Recent Advances in the Treatment of Pediatric Brain Tumors

Central nervous system (CNS) cancers are the second most frequent malignancy in childhood. In recent years, significant advances in surgery, radiotherapy, and chemotherapy have improved survival in children with these tumors. However, a significant proportion of patients with CNS tumors suffer progressive disease despite such treatment.


Sridhar Mani, MD

Latest:

Novel Combinations With Oxaliplatin

Oxaliplatin (Eloxatin) is a novel antineoplastic platinum derivative that may exert its cytotoxic effects by blocking DNA replication/transcription, thus resulting in cell death in proliferating cells, as well as apoptosis.


Sridhar Nadamuni, MSC

Latest:

Researchers identify regulatory protein domains that contribute to tumor cell survival and cancer progression

The p90 ribosomal S6 kinase protein contributes to tumor cell proliferation and survival, the genetic disease Carney complex, and cardiac hypertrophy.


Srinivasan Vijayakumar, MD

Latest:

Follow-up Care for Cancer: Making the Benefits Equal the Cost

The article by Schwartz and colleagues is important and timely, and brings into focus an essential component of the practice of oncology. Posttreatment follow-up is not often emphasized in the training of our residents and fellows, and is often based on


Sriram Yennurajalingam, MD

Latest:

Fatigue and Dyspnea

Fatigue and dyspnea are two of the most common symptoms associated with advanced cancer. Fatigue is also commonly associated with cancer treatment and occurs in up to 90% of patients undergoing chemotherapy.


Srivalli Gopaluni, MD

Latest:

Granulocytic Sarcoma in a Patient With Myelodysplastic Syndrome

Our case illustrates the fact that MDS-associated GS can be treated palliatively with radiation and hypomethylating agents in an appropriate setting. With the growing geriatric patient population, effective treatment options are needed in this disease.


Stacey Douglas, RN

Latest:

Topoisomerase I Inhibitors in the Treatment of Head and Neck Cancer

Traditionally, the role of chemotherapy in the treatment ofsquamous carcinoma of the head and neck has been confined to patients with


Stacy D. Jacobson, MD

Latest:

Pancreatic Cancer in the Older Patient

Pancreatic cancer is a disease seen predominantly in elderly patients. Compared to younger patients, older patients are more likely to present with early-stage disease and, therefore, may be candidates for aggressive local


Stacy Loeb, MD, MSc

Latest:

Active Surveillance of Prostate Cancer

Active surveillance is an excellent alternative to surgery or radiation in patients with low-risk cancers. However, the current methods of ascertaining whether a patient harbors a low-risk cancer are flawed.


Stacy Moulder, MD

Latest:

New Strategies, Targets in Triple-Negative Breast Cancer

This video with Stacy Moulder, MD, highlights efforts to identify various subtypes and molecular targets in triple-negative breast cancer, which could lead to treatment options with already approved agents.


Stamatia Destounis, MD

Latest:

Ductal Carcinoma in Situ

A 57-year-old patient presents for evaluation of right nipple discomfort. The patient has family history of a mother and sister with premenopausal breast cancer.


Stan Brody

Latest:

Prostate ca survivor values regular PSA screeningReaders respond to “Two major studies add fuel to fire of PSA controversy,” April 2009, Cancer Care Practice & Policy, page 8.

Like the vast majority of men, I was “stupid” where my healthcare was concerned. I never asked for a copy of my blood work or questioned the results of my tests. After all, we treat our doctors like gods.